Professionals specializing in Pharmaceuticals and Biotechnology partner with Nerac Analysts at all levels of the research process, from discovery through product lifecycle management.

Nerac’s areas of expertise include:

• Discovery, Preclinical and Clinical Research
• Regulatory Affairs
• Marketing
• Business Development
• Intellectual Property

Review research solutions for Pharmaceutical

Key Nerac Analysts for Pharmaceutical professionals include:

Avis, L. Bridgers, Analyst

“In the wake of a decade or more of acquisitions and mergers in the pharmaceutical industry, and the upheaval of Big Pharma as we once knew it, we see that industry businesses that began as specialty biotechnology companies are more often able to gain a foothold in the marketplace and then morph into successful drug development companies in their growth stage. Those who dare to begin drug development as early-stage companies are often doomed to failure or, at best, early buy-out.”

Avis L. Bridgers partners with pharmaceutical and biotechnology companies and academic technology transfer offices to assess new technologies, grant proposals and business opportunities. With more than 20 years of experience as an innovative researcher, leader, and consultant in the pharmaceutical and biotech industries, she has gained the expertise to identify opportunities and risks, to troubleshoot processes, and to avoid the pitfalls of new ventures. Before joining Nerac, Ms. Bridgers managed a hepatocyte isolation laboratory for a small biotechnology company, headed up an in vitro ADME (absorption, distribution, metabolism and excretion) group for a major contract research organization, and founded a consultancy focused on the use of in vitro models to maximize drug exposure early in the drug development process. In her 15 years at Glaxo and Glaxo-Wellcome, Ms. Bridgers gained expertise in preclinical drug development, bioanalytical method development and instrumentation, and the design and implementation of in vitro absorption and metabolism models.

Areas of Expertise:
Pharmaceuticals
Medical Technology
Molecular Cell Biology
Preclinical Drug Development
In Vitro Absorption Models & Assays
In Vitro Metabolism Models & Assays
Metabolite Isolation & Purification
Transporters & Transport Mechanisms
High-throughout ADME Screening
Delivery of Small Molecule Drugs & Biologics
Isolation & Culture of Primary Cells
Culture of Immortalized Cell Lines
Cell-based Assay Methods
Bioanalytical Methods Development & Instrumentation

Credentials:
M.S., Organic Chemistry, University of North Carolina at Chapel Hill
B.S., Chemistry (Math minor), S.U.N.Y. Oneonta
Member, American Association of Pharmaceutical Scientists (AAPS)

Published:
Ms. Bridgers has published numerous articles in scientific journals, and she is an ad hoc reviewer for Biochemical Pharmacology, Journal of Pharmaceutical Sciences, and Journal of Pharmacology and Experimental Therapeutics.

Richard Hendriks, Ph.D., Analyst

“In the future, as more neurotransmitter receptor subtypes are discovered, drugs are likely to precisely target homologous receptors with increasing specificity, thereby further limiting unwanted side-effects.”

Richard Hendriks, Ph.D., partners with pharmaceutical companies to discover the most recent clinical trials for new agonist or antagonist compounds, and he analyzes prior art in the field of drug combinations to treat certain conditions. His work centers on drug actions, neuroscience, and human and animal studies. He has a Ph.D in neuroscience from University of Melbourne, Australia, and a background in the area of electrophysiology. Dr. Hendriks has received several grants and fellowships from the National Institutes of Health and the National Science Foundation and was a principal investigator for various studies. Dr. Hendriks’ early research focused on neuronal receptor pharmacology, including a compound that was commercialized as Tropisetron. His subsequent research moved to the subject of the central nervous system and included an investigation into the role of potassium channels in embryonic neuronal migration as part of an investigation into potential cures for deafness.

Areas of Expertise:
Pharmaceuticals
Medical Technology
Agriculture

Credentials:
Ph.D., Neuroscience, University of Melbourne, Australia
B.Sc. Hons, Medical Physiology, Flinders University of South Australia
B.Sc., Biophysics, Flinders University of South Australia (FUSA)

Published:
Dr. Hendriks is the author of dozens of published articles and abstracts concerning topics such as physiology and electrophysiology that have appeared in such journals as The Journal of Comparative Neurology, Neuroscience Letters, Biophysical Journal, and the Journal of Neuroscience Research. He has presented abstracts on a variety of subjects to such organizations as the Australian Neuroscience Society, the Australian Physiological and Pharmacological Society, the American Neuroscience Society, American Motility Society, the Biophysical Society, and the Association for Research in Otolaryngology.